269 related articles for article (PubMed ID: 2831259)
1. Multiple molecular forms of phosphodiesterase and the regulation of cardiac muscle contractility.
Weishaar RE; Kobylarz-Singer DC; Quade MM; Steffen RP; Kaplan HR
J Cyclic Nucleotide Protein Phosphor Res; 1986-1987; 11(7):513-27. PubMed ID: 2831259
[TBL] [Abstract][Full Text] [Related]
2. Relationship between inhibition of cardiac muscle phosphodiesterases, changes in cyclic nucleotide levels, and contractile response for CI-914 and other novel cardiotonics.
Weishaar RE; Quade MM; Schenden JA; Evans DB
J Cyclic Nucleotide Protein Phosphor Res; 1985; 10(6):551-64. PubMed ID: 3003170
[TBL] [Abstract][Full Text] [Related]
3. Subclasses of cyclic AMP-specific phosphodiesterase in left ventricular muscle and their involvement in regulating myocardial contractility.
Weishaar RE; Kobylarz-Singer DC; Steffen RP; Kaplan HR
Circ Res; 1987 Oct; 61(4):539-47. PubMed ID: 2820608
[TBL] [Abstract][Full Text] [Related]
4. Subclasses of cyclic AMP phosphodiesterase in cardiac muscle.
Weishaar RE; Kobylarz-Singer DC; Kaplan HR
J Mol Cell Cardiol; 1987 Oct; 19(10):1025-36. PubMed ID: 2830402
[TBL] [Abstract][Full Text] [Related]
5. Modulation of rat thymocyte proliferative response through the inhibition of different cyclic nucleotide phosphodiesterase isoforms by means of selective inhibitors and cGMP-elevating agents.
Marcoz P; Prigent AF; Lagarde M; Nemoz G
Mol Pharmacol; 1993 Nov; 44(5):1027-35. PubMed ID: 8246905
[TBL] [Abstract][Full Text] [Related]
6. Differential modulation of cytokine production by drugs: implications for therapy in heart failure.
Matsumori A; Ono K; Sato Y; Shioi T; Nose Y; Sasayama S
J Mol Cell Cardiol; 1996 Dec; 28(12):2491-9. PubMed ID: 9004165
[TBL] [Abstract][Full Text] [Related]
7. Functional and biochemical evidence for diazepam as a cyclic nucleotide phosphodiesterase type 4 inhibitor.
Collado MC; Beleta J; Martinez E; Miralpeix M; Domènech T; Palacios JM; Hernández J
Br J Pharmacol; 1998 Mar; 123(6):1047-54. PubMed ID: 9559885
[TBL] [Abstract][Full Text] [Related]
8. Modulation of relaxant responses evoked by a nitric oxide donor and by nonadrenergic, noncholinergic stimulation by isozyme-selective phosphodiesterase inhibitors in guinea pig trachea.
Ellis JL; Conanan ND
J Pharmacol Exp Ther; 1995 Mar; 272(3):997-1004. PubMed ID: 7891355
[TBL] [Abstract][Full Text] [Related]
9. Characterization of phosphodiesterase 4 in guinea-pig macrophages: multiple activities, association states and sensitivity to selective inhibitors.
Kelly JJ; Barnes PJ; Giembycz MA
Br J Pharmacol; 1998 May; 124(1):129-40. PubMed ID: 9630352
[TBL] [Abstract][Full Text] [Related]
10. Proteolysis of cyclic AMP phosphodiesterase-II attenuates its ability to be inhibited by compounds which exert positive inotropic actions in cardiac tissue.
Price B; Pyne NJ; Houslay MD
Biochem Pharmacol; 1987 Dec; 36(23):4047-54. PubMed ID: 2825712
[TBL] [Abstract][Full Text] [Related]
11. Initial biochemical and functional characterization of cyclic nucleotide phosphodiesterase isozymes in canine colonic smooth muscle.
Barnette MS; Manning CD; Price WJ; Barone FC
J Pharmacol Exp Ther; 1993 Feb; 264(2):801-12. PubMed ID: 7679736
[TBL] [Abstract][Full Text] [Related]
12. Pig aortic endothelial-cell cyclic nucleotide phosphodiesterases. Use of phosphodiesterase inhibitors to evaluate their roles in regulating cyclic nucleotide levels in intact cells.
Souness JE; Diocee BK; Martin W; Moodie SA
Biochem J; 1990 Feb; 266(1):127-32. PubMed ID: 2155604
[TBL] [Abstract][Full Text] [Related]
13. A potent and selective inhibitor of cyclic AMP phosphodiesterase with potential cardiotonic and antithrombotic properties.
Alvarez R; Banerjee GL; Bruno JJ; Jones GL; Littschwager K; Strosberg AM; Venuti MC
Mol Pharmacol; 1986 Jun; 29(6):554-60. PubMed ID: 3012320
[TBL] [Abstract][Full Text] [Related]
14. Involvement of rolipram-sensitive cyclic AMP phosphodiesterase in the regulation of cardiac contraction.
Muller B; Lugnier C; Stoclet JC
J Cardiovasc Pharmacol; 1990 Nov; 16(5):796-803. PubMed ID: 1703603
[TBL] [Abstract][Full Text] [Related]
15. Effects of phosphodiesterase inhibitors, imidazole and phosphate on cyclic CMP phosphodiesterase are different from those on cyclic AMP and cyclic GMP phosphodiesterases.
Kuo JF; Shoji M; Brackett NL; Helfman DM
J Cyclic Nucleotide Res; 1978 Dec; 4(6):463-74. PubMed ID: 85641
[TBL] [Abstract][Full Text] [Related]
16. The effects of alkylated xanthines on cyclic AMP accumulation in dog thyroid slices exposed to carbamylcholine.
Miot F; Erneux C; Wells JN; Dumont JE
Mol Pharmacol; 1984 Mar; 25(2):261-6. PubMed ID: 6321949
[TBL] [Abstract][Full Text] [Related]
17. Distinct profiles of phosphodiesterase isozymes in cultured cells derived from nonpigmented and pigmented ocular ciliary epithelium.
Bode DC; Hamel LT; Wax MB
J Pharmacol Exp Ther; 1993 Dec; 267(3):1286-91. PubMed ID: 8263791
[TBL] [Abstract][Full Text] [Related]
18. Cyclic AMP-mediated regulation of vascular smooth muscle cell cyclic AMP phosphodiesterase activity.
Rose RJ; Liu H; Palmer D; Maurice DH
Br J Pharmacol; 1997 Sep; 122(2):233-40. PubMed ID: 9313930
[TBL] [Abstract][Full Text] [Related]
19. Insulin activation of cyclic AMP phosphodiesterase in intact ureteral segments.
Weiss RM; Wheeler MA
J Pharmacol Exp Ther; 1988 Nov; 247(2):630-4. PubMed ID: 2846825
[TBL] [Abstract][Full Text] [Related]
20. Phosphodiesterase PDE3 blunts the positive inotropic and cyclic AMP enhancing effects of CGP12177 but not of noradrenaline in rat ventricle.
Vargas ML; Hernandez J; Kaumann AJ
Br J Pharmacol; 2006 Jan; 147(2):158-63. PubMed ID: 16331293
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]